Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease
Targeted Oncology
Reference: Jew S, et al. Target Oncol. 2023;doi:10.1007/s11523-023-00990-6 - James R. Berenson, MD Berenson Cancer...
MedPage Today
All Press
Make an Appointment
Related Articles
American Society of Hematology
Blood Journal: A Phase 1 Trial: Evaluating…Methylprednisolone: RE: ASH 2023 San Diego, CA December 9-11 Media...
MedPage Today
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests...